KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Finished Goods (2016 - 2019)

Pfizer (PFE) has disclosed Finished Goods for 11 consecutive years, with $2.3 billion as the latest value for Q1 2019.

  • On a quarterly basis, Finished Goods fell 19.42% to $2.3 billion in Q1 2019 year-over-year; TTM through Mar 2019 was $2.3 billion, a 19.42% decrease, with the full-year FY2018 number at $2.3 billion, down 21.54% from a year prior.
  • Finished Goods was $2.3 billion for Q1 2019 at Pfizer, up from $2.3 billion in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $2.9 billion in Q4 2017 to a low of $1.8 billion in Q2 2015.
  • A 5-year average of $2.5 billion and a median of $2.6 billion in 2016 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: decreased 24.86% in 2015, then surged 49.89% in 2016.
  • Pfizer's Finished Goods stood at $2.7 billion in 2015, then decreased by 15.51% to $2.3 billion in 2016, then rose by 25.73% to $2.9 billion in 2017, then dropped by 21.54% to $2.3 billion in 2018, then increased by 1.11% to $2.3 billion in 2019.
  • Per Business Quant, the three most recent readings for PFE's Finished Goods are $2.3 billion (Q1 2019), $2.3 billion (Q4 2018), and $2.6 billion (Q3 2018).